Consolidated Statements of Operations - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Income Statement [Abstract]
Research and development	$ 7,594	$ 15,843
General, and administrative	9,393	11,750
Operating expenses	16,987	27,593
Operating loss	(16,987)	(27,593)
Other income (expense):
Other income (expense), net	824	273
Interest expense	(5)	(378)
Other income (expense) total	819	(105)
Loss before benefit from income taxes and noncontrolling interests	(16,168)	(27,698)
Benefit from income taxes	0	(11,527)
Net loss from continuing operations	(16,168)	(16,171)
Discontinued operations - net	0	38,399
Net (loss) income	(16,168)	22,228
Less - net loss from continuing operations attributable to noncontrolling interests	(1)	(182)
Less - net loss from discontinued operations attributable to noncontrolling interests	0	(569)
Net income (loss) attributable to Caladrius Biosciences, Inc. common shareholders	(16,167)	22,979
Amounts Attributable to Caladrius Biosciences, Inc. common shareholders:
Loss from continuing operations	(16,167)	(15,989)
Income from discontinued operations - net of taxes	0	38,968
Net income (loss) attributable to Caladrius Biosciences, Inc. common shareholders	$ (16,167)	$ 22,979
Basic earnings (loss)
Continuing operations (USD per share)	$ (1.67)	$ (1.78)
Discontinued operations (USD per share)	0.00	4.34
Caladrius Biosciences, Inc. common shareholders (USD per share)	$ (1.67)	$ 2.56
Weighted average common shares outstanding:
Basic shares	9,689	8,969
Diluted shares	9,689	8,969